# Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19

> **NCT04292340** · — · UNKNOWN · sponsor: **Shanghai Public Health Clinical Center** · enrollment: 15 (estimated)

## Conditions studied

- Coronavirus

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04292340
- **Lead sponsor:** Shanghai Public Health Clinical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-01
- **Primary completion:** 2020-07-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2020-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04292340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04292340, "Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04292340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*